A Pilot Study of Bevacizumab and Interferon-α2b in Ocular Melanoma

OBJECTIVES: We hypothesized that administration of bevacizumab, a monoclonal antibody that neutralizes vascular endothelial growth factor, in combination with high-dose interferon-alpha2b (IFN-α2b), an inhibitor of basic fibroblast growth factor, would have clinical activity in patients with metasta...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Am J Clin Oncol
Autori principali: Guenterberg, Kristan D., Grignol, Valerie P., Relekar, Kiran V., Varker, Kimberly A., Chen, Helen X., Kendra, Kari L., Olencki, Thomas E., Carson, William E.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2011
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4294796/
https://ncbi.nlm.nih.gov/pubmed/20458209
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/COC.0b013e3181d2ed67
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi